Update on topical photodynamic therapy for skin cancer

Cover Page


Cite item

Full Text

Abstract

Topical photodynamic therapy has become an established therapy option for superficial non-melanoma skin cancers with a substantial evidence base. In this update the increased choice in photosensitizers and light sources are reviewed as well as novel protocols to move beyond lesional treatment and address field therapy. Daylight PDT is emerging as an alternative to conventional office/hospital-based PDT that offers the advantage of much reduced pain. Although most studies have assessed efficacy of PDT in immune-competent patients, there is accumulating evidence for topical PDT being considered an option to assist in reducing the skin cancer burden in organ transplant recipients. The fluorescence associated with photosensitizer application can help delineate lesions prior to full treatment illumination and offers a useful adjunct to treatment in patients where diagnostic uncertainty or poor lesion outline complicates clinical care. PDT may also offer significant benefit in delaying/preventing new cancer development and combined with its recognized photo-rejuvenating effects, is emerging as an effective therapy capable of clearing certain superficial skin cancers, potentially preventing new lesions as well as facilitating photo-rejuvenating effects in treated areas.

About the authors

C. A. Morton

Stirling Community Hospital

Author for correspondence.
Email: colin.morton@nhs.net
Russian Federation

R. -M. Szeimies

Klinikum Vest GmbH

Email: noemail@neicon.ru
Russian Federation

L. R. Braathen

Dermatology Bern

Email: noemail@neicon.ru
Russian Federation

References

  1. Braathen Lasse R., Szeimies Rolf M., Basset Seguin N. et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: An international consensus. J Am Acad Dermatol, 2007; 56: 125-43.
  2. Morton C.A., McKenna K.E., Rhodes L.E. Guidelines for topical photodynamic therapy Br J Dermatol 2008; 159: 1245-66.
  3. Morton C.A., Szeimies R.-M., Sidoroff A. and Braathen L.R., European guidelines for topical photodynamic therapy part 1: treatment delivery and current indications - actinic keratoses, Bowen’s disease, basal cell carcinoma. JEADV 2013; 27: 536-544.
  4. Morton C.A., Szeimies R.-M., Sidoroff A. and Braathen L.R., European guidelines for topical photodynamic therapy part 2: emerging indications - field cancerization, photorejuvenation and inflammatory/ infective dermatoses. JEADV 2013; 27: 672-679.
  5. Dragieva C., Hafner J., Dummer R. et al. Topical photodynamic therapy in the treatment of actinic keratoses and Bowen’s disease in transplant recipients. Transplantation 2004; 77: 115-21.
  6. Kennedy J.C., Pottier R.H., Pross D.C. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience J Photochem Photobiol B. 1990; 6: 143-8.
  7. Henderson B.W., Dougherty T.J. How does photodynamic therapy work? Photochem Photobiol 1992; 55: 145-57.
  8. Maisch T., Moor A.C., Regensburger J. et al. Intense pulse light and 5-ALA PDT: phototoxic effects in vitro depend on the spectral overlap with protoporphyrin IX but do not match cut-off filter notations. Lasers Surg Med. 2011; 43: 176-82.
  9. Dirschka T., Radny P., Dominicus R. et al. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratoses: results of a multicentre, randomized, observer-blind phase III study in comparison with registered methyl-5-aminolaevulinate cream and placebo. Br J Dermatol 2012; 166: 137-46.
  10. Szeimies R.M., Radny P., Sebastian M. et al. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study. Br J Dermatol. 2010; 163: 386-94.
  11. Wiegell S.R., Wulf H.C., Szeimies R.-M., Basset-Seguin N., Bissonnette R., Gerritsen M.-J.P., Gilaberte Y., Calzavara-Pinton P., Morton C.A., Sidoroff A. and Braathen L.R. Daylight photodynamic therapy for actinic keratosis: an international consensus. JEADv 2012; 26: 673-679.
  12. Neittaanmäki-Perttu N., Karppinen T.T., Grönroos M., Tani T.T., Pölönen I., Snellman E. Daylight photodynamic therapy for actinic keratoses: A randomized double-blinded non-sponsored prospective study comparing BF-200 aminolevulinic acid with methyl-5-aminolaevulinate Br J Dermatol. 2014 Aug doi: 10.1111/bjd.13326. [Epub ahead of print]
  13. Ibbotson S.H., Ferguson J. Ambulatory photodynamic therapy using low irradiance inorganic light-emitting diodes for the treatment of non-melanoma skin cancer: an open study. Photodermatol Photoimmunol Photomed. 2012; 28: 235-9.
  14. Fritsch C.J., Ruzicka T. Fluorescence diagnosis and photodynamic therapy in dermatology from experimental state to clinic standard methods Envtl Path, Tox & Oncol 2006; 25; 425-39.
  15. Neus S., Ambichler T., Bechara F.G., Wohl S., Lehmann P. Preoperative assessment of basal cell carcinoma using conventional fluorescence diagnosis Arch Derm Res 2009; 301: 289-94.
  16. Lee C.Y., Kim K.H., Kim Y.H. The efficacy of photodynamic therapy in delineating the lateral border between a tumour and a tumour-free area during Mohs micrographic surgery Dermatologic Surgery 2010; 36: 1704-10.
  17. Tyrrell J.S., Campbell S.M., Curnow A. The relationship between protoporphyrin IX photobleaching during real-time dermatological methyl-aminolevulinate photodynamic therapy (MAL-PDT) and subsequent clinical outcome Lasers Surg Med; 2010; 42: 613-9.
  18. Wiegell S.R., Skiveren P.A., Philipsen P.A. and Wulf H.C. Pain during photodynamic therapy is associated with protoporphyrin IX fluorescence and fluence rate. Br J Dermatol 2008; 158: 727-33.
  19. http://www.medicines.org.uk/emc/medicine/11913/ SPC accessed 11/11/14
  20. http://www.ema.europa.eu/docs/en_GB/docu-ment_library/EPAR_- _Product_Information/hu-man/002204/WC500120044.pdf accessed 11/11/14
  21. http://www.mhra.gov.uk/home/groups/spcpil/docu-ments/spcpil/con1356931026870.pdf. accessed 01/10/14
  22. http://www.dusapharma.com/kerastick.html accessed 11/11/14.
  23. http://www.galderma.com.au/Portals/4/PIs%20 and%20CMIs/Metvix%20cream_PI%20_140826.pdf accessed 11/11/14.
  24. Cochrane C., Mordon S.R., Lesage J.C., Koncar V. New design of textile light diffusers for photodynamic therapy. Mater Sci Eng C Mater Biol Appl. 2013; 33: 1170-5.
  25. de Bruijn H.S., Meijers C., van der Ploeg-van den Heuvel A. et al. Microscopic localisation of protoporphyrin IX in normal mouse skin after topical application of 5-aminolevulinic acid or methyl 5-ami-nolevulinate J Photochem Photobiol B. 2008; 92: 91-7.
  26. de Vijlder H.C., Sterenborg H.J., Neumann H.A., Robinson D.J. de Haas ER. Light fractionation significantly improves the response of superficial basal cell carcinoma to aminolaevulinic acid photodynamic therapy: five-year follow-up of a randomized, prospective trial. Acta Dermato-Venereologica. 2012; 92: 641-7.
  27. de Haas ER, Sterenborg HJ, Neumann HA, Robinson DJ. Response of Bowen disease to ALA-PDT using a single and a 2-fold illumination scheme. Arch Dermatol 2007; 143: 264-5.
  28. de Haas E.R., de Vijlder H.C., Sterenborg H.J. et al. Fractionated aminolevulinic acid-photodynamic therapy provides additional evidence for the use of PDT for non-melanoma skin cancer. J Eur Acad Dermatol Venereol 2008; 22: 426-30.
  29. Sotiriou E., Apalla Z., Chovarda E. et al. Single vs. fractionated photodynamic therapy for face and scalp actinic keratoses: a randomized, intraindividual comparison trial with 12 month follow-up J Eur Acad Dermatol Venereol 2012; 26: 36-40.
  30. Mosterd K., Thissen MRTM, Nelemans P. et al. Fractionated 5-aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial Br J Dermatol 2008; 159: 864-70.
  31. Szeimies R.M., Stockfleth E., Popp G. et al. Longterm follow-up of photodynamic therapy with a self-adhesive 5-aminolaevulinic acid patch: 12 months data. Br J Dermatol 2010; 162: 410-4.
  32. Tschen E.H., Wong D.S., Pariser D.M. et al. The Phase IV ALA-PDT Actinic Keratosis Study Group. Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follow up. Br J Dermatol 2006; 155: 1262-9.
  33. Morton C., Campbell S., Gupta G. et al. Intraindividual, right-left comparison of topical methyl aminolaevulinatephotodynamic therapy and cryotherapy in subjects with actinic keratoses: a multicentre, randomized controlled study. Br J Dermatol 2006; 155: 1029-36.
  34. Piacquadio D.J., Chen D.M., Farber H.F. et al. Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded phase 3 multicenter trials. Arch Dermatol 2004; 140: 41-6.
  35. Dirschka T., Radny P., Dominicus R. et al. Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis. Br J Dermatol, 2013; 168: 825-836.
  36. Hauschild A., Stockfleth E., Popp G. et al. Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies Br J Dermatol. 2009; 160: 1066-1074.
  37. Wiegell S.R., Haedersdal M., Philipsen P.A. et al. Continuous activation of PpIX by daylight is as effective as and less painful than conventional photodynamic therapy for actinic keratoses; a randomized, controlled, single-blind study. Br J Dermatol 2008; 158: 740-6.
  38. Wiegell S.R., Fabricius S., Stender I.M. et al. A randomized, multicentre study of directed daylight exposure times of 1 1/2 vs. 2 1/2 h in daylight-mediated photodynamic therapy with methyl aminolaevulinate in patients with multiple thin actinic keratoses of the face and scalp Br J Dermatol 2011; 164: 1083-90.
  39. Wiegell S.R., Fabricius S., Gniadecka M. et al. Daylight-mediated photodynamic therapy of moderate to thick actinic keratoses of the face and scalp - a randomized multicentre study. Br J Dermatol 2012; 166: 1327-32.
  40. Wiegell S.R., Fabricius S., Heydenreich J. et al. Weather conditions and daylight-mediated photodynamic therapy: protoporphyrin IX-weighted daylight doses measured in six geographical locations. Br J Dermatol 2013, 168: 186-91.
  41. Sotiriou E., Apalla Z., Chovarda E. Panagiotidou D., Ioannides D. Photodynamic therapy with 5-aminolevu-linic acid in actinic cheilitis: an 18 month clinical and histological follow-up. J Eur Acad Dermatol Venereol 2010; 24: 916-20.
  42. Berking C., Herzinger T., Flaig M.J. et al. The efficacy of photodynamic therapy in actinic chielitis of the lower lip: a prospective study of 15 patients. Dermatol Surg 2007; 33: 825-30.
  43. Calzavara-Pinton P.G., Rossi M.T., Sala R. et al. A retrospective analysis of real-life practice of off-label photodynamic therapy using methyl aminolevulinate (mAl-PDT) in 20 Italian dermatology departments. Part 2: Oncologic and infectious indications. J Photochem Photobiol Sci. 2013; 12: 158-165.
  44. Sotiriou E., Lallas A., Gooussi C. et al. Sequential use of photodynamic therapy and imiquimod 5% cream for the treatment of actinic cheilitis; a 12 month follow-up study. Br J Dermatol 2011; 165: 888-92.
  45. http://www.euroderm.org/images/stories/guidelines/ guideline_Management_Actinic_Keratoses-up-date2011.pdfaccessed 11/11/14.
  46. De Berker D., McGregor J., Hughes B. Guidelines for the management of actinic keratosis. Br J Dermatol, 2007; 156: 222-230.
  47. Morton C.A., Horn M., Leman J. et al. A randomized, placebo-controlled, European study comparing MAL-PDT with cryotherapy and 5-fluorouracil in subjects with Bowen's disease. Arch Dermatol 2006; 142: 729-35.
  48. Lehmann P. Methyl aminolaevulinate-photodynamic therapy: a review of clinical trials in the treatment of actinic keratoses and nonmelanoma skin cancer. Br J Dermatol 2007; 156: 793-801.
  49. Calzavara-Pinton P.G., Venturini M., Sala R. et al. Methylaminolaevulinate-based photodynamic therapy of Bowen's disease and squamous cell carcinoma. Br J Dermatol 2008; 159: 137-44.
  50. Truchuelo M., Fernandez-Guarino M., Fleta B. et al. Effectiveness of photodynamic therapy in Bowen's disease: an observational and descriptive study in 51 lesions. J Eur Acad Dermatol Venereol 2012; 26: 868-74.
  51. Cavicchini S., Serini S.M., Fiorani R. et al. Long-term follow-up of metil aminolevulinate (MAL)-PDT in difficult-to-treat cutaneous Bowen's disease. Int J Dermatol 2011; 50: 1002-5.
  52. Lopez N., Meyer-Gonzalez T., Herrera-Acosta E. et al. Photodynamic therapy in the treatment of extensive Bowen's disease. J Dermatolog Treat 2012: 23: 428-30.
  53. Morton C.A., Whitehurst C., McColl J.H. et al. Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma. Arch Dermatol 2001; 137: 319-24.
  54. Morton C.A., Birnie A.J., Eedy D.J. British Association of Dermatologists' guidelines for the management of squamous cell carcinoma in situ (Bowen's disease) 2014. Br J Dermatol 2014; 170: 245-60.
  55. Basset-Séguin N., Ibbotson S.H., Emtestam L. et al. Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial E J Dermatol 2008; 18: 547-53.
  56. Szeimies R., Ibbotson S., Murrell D. et al. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20mm), with a 12-month follow-up. J Eur Acad Dermatol Venereol 2008; 22: 1302-1311.
  57. Rhodes L.E., de Rie M., Enstrom Y. et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. Arch Dermatol 2004; 140: 17-23.
  58. Rhodes L.E., de Rie M.A., Leifsdottir R. et al. Five year follow up of a randomized prospective trial of topical methyl aminolevulinate-photodynamic therapy versus surgery for nodular basal cell carcinoma. Arch Dermatol, 2007; 143, 1131-1136.
  59. Foley P., Freeman M., Menter A. et al. Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studies Int J Dermatol 2009; 48: 1236-45.
  60. Fantini F., Greco A., Del Giovane C. et al. Photodynamic therapy for basal cell carcinoma: clinical and pathological determinants of response. J Eur Acad Dermatol Venereol 2011; 25: 896-901.
  61. Wiegell S.R., Skedt V., Wulf H.C. Daylight-mediated photodynamic therapy of basal cell carcinomas - an explorative study. J Eur Acad Dermatol Venereol. 2013. doi: 10.1111/jdv.12076. 34 L № 6, 2014
  62. Peng Q., Warloe T., Berg K. et al. 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer 1997; 79: 2282-308.
  63. Morton C.A., Whitehurst C., McColl J.H., Moore J.V., MacKie R.M. Photodynamic therapy for basal cell carcinoma - Effect of tumour thickness and duration of photosensitiser application on response. Arch Dermatol, 1998, 134, 248-9.
  64. Vinciullo C., Elliott T., Francis D. et al. Photodynamic therapy with topical methyl aminolaevulinate for 'difficult-to-treat' basal cell carcinoma. Br J Dermatol 2005; 152: 765-72.
  65. Arits A.H., Mosterd K., Essers B.A. et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncology. 2013; 14: 647-54.
  66. Loncaster J., Swindell R., Slevin F. et al. Efficacy of photodynamic therapy as a treatment for Gorlin Syndrome-related basal cell carcinomas. Clinical Oncology 2009; 21: 502-8.
  67. http://www.euroderm.org/images/stories/guidelines/ guideline_Basal_Cell_Carcinoma-update2012%20. pdf Last accessed 01/10/14.
  68. Telfer N., Colver G. and Morton C. Guidelines for the management of basal cell carcinoma. Br J Dermatol, 2008; 159: 35-48.
  69. Dragieva C., Prinz B.M., Hafner J. et al. A randomized controlled clinical trial of topical photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratoses in transplant recipients. Br J Dermatol 2004; 151: 196-200.
  70. Piaserico S., Belloni Fortina A., Rigotti P. et al. Topical photodynamic therapy of actinic keratosis in renal transplant patients. Transplant Proc 2007; 39: 1847-50.
  71. Perrett C.M., McGregor J.M., Warwick J. et al. Treatment of post-transplant premalignant skin disease: A randomized intrapatient comparative study of 5-fluo-rouracil cream and topical photodynamic therapy. Br J Dermatol 2007; 156: 320-8.
  72. Schleier P., Hyckel P., Berndt A. et al. Photodynamic therapy of virus-associated epithelial tumours of the face in organ transplant recipients. J Cancer Res Clin Oncol 2004; 130: 279-284.
  73. Wulf H.C., Pavel S., Stender I., Bakker-Wensveen CAHB. Topical photodynamic therapy for prevention of new skin lesions in renal transplant recipients. Acta Derm Venereol 2006; 86: 25-28.
  74. Wennberg A.M., Stenquist B., Stockfleth E. et al. Photodynamic therapy with methyl aminolevulinate for prevention of new lesions in transplant recipients: a randomized study. Transplantation 2008; 86: 423-9.
  75. De Graaf YGL, Kennedy C., Wolterbeek R. et al. Photodynamic therapy does not prevent cutaneous squamous-cell carcinoma in organ-transplant recipients: results of a randomized-controlled trial. J Invest Dermatol 2006; 126: 569-574.
  76. Willey A., Mehta S., Lee P.K. Reduction in incidence of squamous cell carcinoma in solid organ transplant recipients treated by cyclic Photodynamic therapy. Dermatol Surg 2010; 36: 652-8.
  77. Braathen L., Morton C., Basset-Seguin N. et al. Photodynamic therapy for skin field cancerization: an international consensus. International Society for Photodynamic Therapy in Dermatology. J Eur Acad Dermatol Venereol 2012; 26: 1063-6.
  78. Basset-Seguin N., Baumann Conzett K., Gerritsen MJP, et al. Photodynamic therapy for actinic keratoses in organ transplant recipients. J Eur Acad Dermatol Venereol 2013; 27: 57-66.
  79. Apalla Z., Sotiriou E., Chovarda E., Lefaki I., Devliotou- Panagiotidou D. and loannides D. Skin cancer: preventive photodynamic therapy in patients with face and scalp cancerization. A randomized placebo-controlled study. Br J Dermatol. 2010; 162: 171-175.
  80. Bagazgoitia L., Cuevas Santos J., Juarranz A., Jaen P. Photodynamic therapy reduces the histologic features of actinic damage and the expression of early oncogenic markers. Br J Dermatol 2011; 165: 144-15;
  81. Szeimies R.M., Torezan L., Niwa A. et al. Clinical, histopathological and immunohistochemical assessment of human skin field cancerization before and after photodynamic therapy.Br J Dermatol. 2012; 167: 150-9.
  82. Edstrom D.W., Porwit A., Ros A.M. Photodynamic therapy with topical 5-aminolevulinic acid for mycosis fungoides: clinical and histological response. Acta Derm Venereol 2001; 81: 184-8.
  83. Zane C., Venturini M., Sala R., Calzavara.Pinton P. Photodynamic therapy with methylaminolevulinate as a valuable treatment option for unilesional cutaneous T-cell lymphoma. Photodermatol Photoimmunol Photomed 2006; 22: 254-8.
  84. Fernandez-Guarino M., Harto A., Perez-Garcia B., Montull C., De Las Heras E., Jaen P. Plaque-phase mycosis fungoides treated with photodynamic therapy: results in 12 patients. Actas Dermosifilogr 2010; 101: 785-91.
  85. Kim S.T., Kang D.Y., Kang J.S., Baek J.W., Jeon Y.S., Suh K.S. Photodynamic Therapy with Methyl-aminolaevulinic Acid for Mycosis Fungoides. Acta Derm Venereol 2012; 92: 264-8.
  86. Quéreux G., Brocard A., Saint-Jean M. et al. Photodynamic therapy with methyl-aminolevulinic acid for paucilesional mycosis fungoides: A prospective open study and review of the literature. J Am Acad Dermatol. 2013; 69: 890-7.
  87. Paoli J., Ternesten Bratel A., Lowhagen G-B et al. Penile intraepithelial neoplasia: results of photodynamic therapy. Acta Derm Venereol 2006; 86: 418-21.
  88. Shieh S., Dee A.S., Cheney R.T. et al. Photodynamic therapy for the treatment of extramammary Paget’s disease. Br J Dermatol 2002; 146: 1000-5.
  89. Rapagliesi F., Fontanelli R., Rossi G. et al. Photodynamic therapy using a methyl ester of 5-aminolaevu-linic acid in recurrent Paget’s disease of the vulva: a pilot study. Gynecol Oncol 2006; 103: 581-6.
  90. Zawislak A.A., McCarron P.A., McCluggage W.G. et al. Successful photodynamic therapy of vulval Paget’s disease using a novel patch-based delivery system containing 5-aminolevulinic acid. Br J Obstet Gynaecol 2004; 111: 1143-5.
  91. Grapengiesser S., Ericson M., Gudmundsson F. et al. Pain caused by photodynamic therapy of skin cancer. Clin Exp Dermatol 2002; 27: 493-497.
  92. Sandberg C., Stenquist B., Rosdahl I. et al. Important factors for pain during photodynamic therapy for actinic keratosis. Acta Derm Venereol 2006; 86: 404-408.
  93. Warren C.B., Karai L.J., Vidmos A., Maytin E.V. Pain associated with aminolevulinic acid-photodynamic therapy of skin disease. J Am Acad Dermatol 2009; 61: 1033-1043.
  94. Halldin C.B., Gillstedt M., Paoli J. et al. Predictors of pain associated with photodynamic therapy: a retrospective study of 658 treatments. Acta Derm Venereol 2011; 91: 545-551.
  95. Gaal M., Otrosinka S., Baltas E. et al. Photodynamic therapy of nonmelanoma skin cancer with methyl aminolavulinate is associated with less pain than with aminolaevulinic acid. Acta Derm Venereol 2012; 92: 173-175.
  96. Gholam P., Weberschock T., Denk K., Enk A. Treatment with 5-aminolaevulinic acid methylester is less painful than treatment with 5-aminolaevulinic acid nanoemulsion in topical photodynamic therapy for actinic keratosis. Dermatology 2011; 222: 358-362.
  97. Holmes M., Dawe R.S., Ferguson J., Ibbotson S.H. A randomized, double-blind, placebo-controlled study of the efficacy of tetracaine gel (Ametop) for pain relief during topical photodynamic therapy. Br J Dermatol 2004; 150: 337-340.
  98. Langan S.M., Collins P. Randomized, double-blind, placebo-controlled prospective study of the efficacy of topical anaesthesia with a eutectic mixture of lignocaine 2.5% and prilocaine 2.5% for topical 5-aminolae-vulinic acid-photodynamic therapy for extensive scalp actinic keratoses. Br J Dermatol 2006; 154: 146-149.
  99. Skiveren J., Haedersdal M., Philipsen P.A. et al. Morphine gel 0.3% does not relieve pain during topical photodynamic therapy: a randomized double-blind, placebo controlled study. Acta Derm Venereol 2006; 86: 409-411.
  100. Pagliaro J., Elliott T., Bulsara M. et al. Cold air analgesia in photodynamic therapy of basal cell carcinomas and Bowen’s disease: an effective addition to treatment: a pilot study. Dermatol Surg 2004; 30: 63-66.
  101. Paoli J., Halldin C., Ericson M.B., Wennberg A.M. Nerve blocks provide effective pain relief during photodynamic therapy for extensive facial actinic keratoses. Clin Exp Dermatol 2008; 33: 559-564.
  102. Halldin C.B., Paoli J., Sandberg C., Gonzalez H., Wennberg A.M. Nerve blocks enable adequate pain relief during topical photodynamic therapy of field cancerization on the forehead and scalp. Br J Dermatol 2009; 160: 795-800.
  103. Serra-Guillen C., Hueso L., Nagore E. et al. Comparative study between cold air analgesia and supraorbital and supratrochlear nerve block for the management of pain during photodynamic therapy for actinic keratoses of the frontotemporal zone. Br J Dermatol 2009; 161: 353-356.
  104. Golub A.L., Gudgin D.E., Kennedy J.C. et al. The monitoring of ALAinduced protoporphyrin IX accumulation and clearance in patients with skin lesions by in vivo surface-detected fluorescence spectroscopy. Lasers Med Sci 1999; 14: 112-122.
  105. Angell-Peterson E., Christensen C., Mullet C.R., Warloe T. Phototoxic reaction and porphyrin fluorescence in skin after topical application of methyl aminolaevulinate. Br J Dermatol 2006; 156: 301-307.
  106. Wulf H.C., Philipsen P. Allergic contact dermatitis to 5-aminolaevulinic acid methylester but not to 5-ami-nolaevulinic acid after photodynamic therapy. Br J Dermatol 2004; 150: 143-145.
  107. Harries M.J., Street G., Gilmour E. et al. Allergic contact dermatitis to methyl aminolevulinate (Metvix) cream used in photodynamic therapy. Photodermatol Photoimmunol Photomed 2007; 23: 35-36.
  108. Hohwy T., Andersen K.E., Solvsten H., Sommerlund M. Allergic contact dermatitis to methyl aminolevulinate after photodynamic therapy in 9 patients. Contact Derm 2007; 57: 321-323.
  109. Korshoj S., Solvsten H., Erlandsen M., Sommerlund M. Frequency of sensitization to methyl aminolaevulinate after photodynamic therapy. Contact Derm 2009; 60: 320-324.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Morton C.A., Szeimies R.-., Braathen L.R.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 60448 от 30.12.2014.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies